**GUIDELINES FOR BREASTFEEDING MOTHERS IN NUCLEAR MEDICINE**

**LATEST REVISION DATE: 9/3/96**

The material in this document has been developed as part of a NUREG
document (1492). The data in this document may also be quoted as a
personal communication from the Radiation Internal Dose Information
Center. Please contact the center with any questions or comments about
the data.

Richard E. Toohey, 423-576-3448 phone, 423-576-8673 fax,
tooheyr@orau.gov e-mail

Audrey T. Stelson, 423-576-3450 phone, 423-576-8673 fax,
stelsona@orau.gov e-mail

Please note that the area code changes from 423 to 865 effective 1
October 1999.

Table 1

Summary of the Effective Dose Equivalents to Newborns

and One-Year-Olds Used in This Report

[Effective Dose Equivalent\* (rem/mCi)]{.underline}

[Radiopharmaceutical]{.underline} [Newborn]{.underline}
[One-Year-Old]{.underline}

Ga‑67 Citrate 6.7 2.69

Tc‑99m DTPA 0.13 0.056

Tc‑99m MAA 0.63 0.26

Tc‑99m Pertechnetate 0.41 0.19

I‑131 Sodium Iodide (NaI) 20000^\*\*^ 14000^\*\*^

Cr‑51 EDTA 0.11 0.048

Tc‑99m DISIDA 0.85 0.41

Tc‑99m glucoheptonate 0.16 0.36

Tc‑99m HAM 0.56 0.23

Tc‑99m MIBI 0.52 0.24

Tc‑99m MDP 0.41 0.16

Tc‑99m PYP 0.28 0.12

Tc‑99m RBC - in vivo labeling 0.30 0.14

Tc‑99m RBC - in vitro labeling 0.31 0.14

Tc‑99m Sulfur Colloid 0.74 0.36

In‑111 White Blood Cells 33 13

I‑123 Sodium Iodide (NaI) 5.9 4.1

I‑123 OIH 0.24 0.10

I‑123 mIBG 5.9 4.1

I‑125 OIH 0.89 0.36

I‑131 OIH 1.1 0.44

Tc‑99m DTPA Aerosol 0.28 0.12

Tc‑99m MAG3 0.12 0.052

Tc‑99m White Blood Cells 0.41 0.19

Tl-201 Chloride 15 8.5

\* Effective dose equivalent to the infant per unit activity
administered

intravenously to the infant.

\*\* Dose to the infant\'s thyroid per unit activity administered
intravenously

(or orally) to the infant (rad/mCi).

Table 2

[Classification of Radiopharmaceuticals]{.underline}

[Class A]{.underline} [Class B]{.underline} [Class C]{.underline}

Ga-67 Citrate Cr-51 EDTA Tc-99m DTPA Aerosol

Tc-99m DTPA Tc-99m DISIDA Tc-99m MAG3

Tc-99m pertechnetate (TcO~4~^-^) Tc-99m glucoheptonate Tc-99m WBC

Tc-99m MAA Tc-99m HAM Xe-133 gas

I-131 NaI Tc-99m MDP/HDP

Tc-99m MIBI

Tc-99m PYP

Tc-99m RBC

Tc-99m sulphur colloid

In-111 WBC

I-123 NaI

I-123 OIH

I-123 mIBG

I-125 OIH

I-131 OIH

Tl-201 chloride

Table 3

[Biokinetic Parameters for Radiopharmaceuticals Excreted in Breast
Milk]{.underline}

[Excretion Fraction\*]{.underline}

[Class A]{.underline} [Lowest]{.underline} [Highest]{.underline} T~B~
(h) [Reference]{.underline}

Ga-67 Citrate 9.5E-5 (72) 216 TO76

2.7E-5 (38) 3.7E-5 (58) 82-385 RUB94

5.6E-5 (96) LA71

1.0E-4 (88) GR83

4.3E-5 (48) WWE94

3.16E-2§§ 9.9E-2§§ 20-390 RUB94

Tc-99m DTPA 7.2E-7 (2.2) 15 MO84‡

6.0E-7 (2.8) 15 MO85

5.0E-4§§ 2.4E-3§§ 6.5-30 RUB94

\~5.0E-7 (\~3) 9.6 AH85

Tc-99m MAA 1.4E-4 (2.2) 20 MO84

7.1E-6 (5) 3.1E-4 (7) 5.2-45 MA81

2.4E-5 (4) 5.3 BE73

1.4E-4 (3.5) 12\*\* CRA85

7.0E-6 (6) \~12 HEA79

4.0E-3§§ 5.2E-2§§ 7.3-18 AH85

Tc-99m pertechnetate \~6.7E-6 (8.5) RUM78

2.6E-5 (10) 6.4E-5 (2) 9-66 WY73

1.4E-4 (22) 20 VA71

\~1.3E-5 (3) PI79

7.19E-3 (2.4) 1.7E-2 (2) OG83†

\~5.0E-4 (\~5) 6.9 AH85

1.7E-4 (8.2) 6 MO87

1.4E-4 (\~3) 5.2 HED86

I-131 NaI 1.4E-5 (24) 4.0E-5 (6) \~9.9 NU52

6.7E-4 (6) WEA60

6.6E-4 12 DY88 (2 comp

\+ 1.6E-5 526 model)

3.0E-2 (18) \~9.4 RUB88

\~5.0E-4 13 ROB94 (diag.)

11 ROB94 (ther.

235 2 comp model

2.3E-1§§ 117 RUB94

2.5E-1§§ 4.6E-1§§ 7.6-12 MO89a

Table 3 (Cont\'d)

[Biokinetic Parameters for Radiopharmaceuticals Excreted in Breast
Milk]{.underline}

[Excretion Fractions\*]{.underline} [Reference]{.underline}

[Class B]{.underline} [Lowest]{.underline} [Highest]{.underline} T~B~
(h) (see ref)

Cr-51 EDTA 1.5E-4§§ 6.5E-4§§ 5.0-7.0 AH85

Tc-99m DISIDA 1.0E-3§§ 2.8E-3§§ 10-(9.1)†† RUB94

Tc-99m glucoheptonate 1.4E-3§§ 9.0 RUB94

2.6E-6 12 MO87

Tc-99m HAM 8.8E-3§§ 1.1E-2§§ 6.0-(7.0)†† RUB94

Tc-99m MIBI 1.4E-6 (3.3) 23 RUB91§

1.0E-4§§ 3.0E-4§§ 18-(6.7)†† RUB94

Tc-99m MDP/HDP \~1.6E-6 (\~4) 8.4-34 AH85

Tc-99m PYP 1.5E-3§§ 4.4E-3§§ 8.4-(6.8)†† RUB94

Tc-99m RBC - in vivo 6.0E-3§§ 1.0E-2§§ (7.7)†† ROS90

4.5E-5 (8) (6.8)†† ROS90

\~1.0E-7 (\~4) (7)†† AH85

Tc-99m RBC - in vitro 2.0E-4§§ 3.0E-4§§ (7.8-9.0)†† RUB94

Tc-99m Sulphur Colloid 1.6E-3§§ 1.5E-2§§ 35-(8.3)†† RUB94

In-111 WBC 3.3E-7 (13) (85.3)†† MO85

7.3E-7 (16) (140)†† HES88

2.4E-7 (20) BU86

I-123 NaI 2.6E-2§§ 10.4 HED86

6.5E-5 10.4 HED86

I-123 OIH 6.0E-5 4.8 MO89

1.2E-02§§ 3.5E-2§§ 8.1-10.2 ROS90

1.5E-4 (4) 8.3 ROS90

I-123 mIBG 7.2E-6 (8) 85 KE94

I-125 OIH 2.4E-2§§ 4.8 AH85

I-131 OIH 1.8E-2§§ 4.9E-2§§ 2.2-6.0 AH95

Tl-201 Chloride 2.2E-6 43 MU89#

\+ 1.9E-7 (362)††

1.8E-6 13 JO95#

\+ 9.8E-7 164

Table 3 (Cont\'d)

[Biokinetic Parameters for Radiopharmaceuticals Excreted in Breast
Milk]{.underline}

[Class C]{.underline}

Tc-99m DTPA Aerosol Fraction of administered aerosol assumed to reach

bloodstream (0.406) treated as Tc-99m DTPA

Tc-99m MAG3 Treated as Tc-99m DTPA (renal agent for which data exist)

Tc-99m WBC Treated as Tc-99m pertechnetate, as fraction of free Tc-99m

is highly variable

Xe-133 gas See text

\* Peak fraction per ml of milk. All values corrected to the time of
activity

administration. The number in parenthesis is the time (h) at which this

maximum was observed. \"Lowest\" is the lowest concentration observed at

peak, and \"Highest\" is the highest concentration observed at peak, in
an

individual patient. If data from only one patient are reported, they are

given under the \"Highest\" column.

\*\* Pooled data from 4 patients

† Patient admitted for study of enlarged thyroid.

‡ Conservative value chosen due to anecdotal report (n=1) (see addendum
of

MO84

§ Data in Table 1 of RUB91 recalculated due to possible errors in
derived

values for the percent excreted in milk.

§§ Total fraction excreted - milk concentrations not given

(t)†† Effective half-time \> T~P~ indicates continued activity
accumulation

Speciation tests indicated that the activity excreted was most likely in
the

form of NaI, [not]{.underline} mIBG.

\# 2 Compartment Model

Table 4

Cumulative Activity Ingested and Radiation Doses Received

from the Radiopharmaceuticals Considered in this Report

Under Different Interruption Schedules

> Cumulative Activity Effective Dose
>
> Interruption [Ingested]{.underline} [Equivalent (mrem)]{.underline}
>
> [Time (hr)]{.underline} [mCi]{.underline} [percent]{.underline}
> [Newborn]{.underline} [1-Yr-Old]{.underline}
>
> Ga‑67 Citrate, A(0) = 5 mCi, min concentration, half-time:
>
> 3 4.09E‑02 8.17E‑01 2.72E+02 1.04E+02
>
> 12 2.76E‑02 5.52E‑01 1.84E+02 7.05E+01
>
> 24 1.64E‑02 3.28E‑01 1.09E+02 4.18E+01
>
> 48 5.77E‑03 1.15E‑01 3.84E+01 1.47E+01
>
> 96 7.14E‑04 1.43E‑02 4.76E+00 1.82E+00
>
> 120 2.51E‑04 5.03E‑03 1.67E+00 6.42E‑01
>
> 168 3.11E‑05 6.23E‑04 2.07E‑01 7.95E‑02
>
> 336 2.08E‑08 4.17E‑07 1.39E‑04 5.32E‑05
>
> 672 9.27E‑15 1.85E‑13 6.17E‑11 2.37E‑11
>
> Ga‑67 Citrate, A(0) = 5 mCi, max concentration, half-time:
>
> 3 1.99E+00 3.98E+01 1.33E+04 5.08E+03
>
> 12 1.81E+00 3.62E+01 1.20E+04 4.62E+03
>
> 24 1.59E+00 3.18E+01 1.06E+04 4.06E+03
>
> 48 1.23E+00 2.47E+01 8.21E+03 3.15E+03
>
> 96 7.40E‑01 1.48E+01 4.93E+03 1.89E+03
>
> 120 5.73E‑01 1.15E+01 3.82E+03 1.46E+03
>
> 168 3.44E‑01 6.88E+00 2.29E+03 8.78E+02
>
> 336 5.76E‑02 1.15E+00 3.83E+02 1.47E+02
>
> 672 1.61E‑03 3.23E‑02 1.07E+01 4.12E+00
>
> Tc‑99m DTPA, A(0) = 20 mCi, min concentration, half-time:
>
> 3 2.57E‑03 1.29E‑02 3.23E‑01 1.43E‑01
>
> 12 3.49E‑04 1.74E‑03 4.39E‑02 1.94E‑02
>
> 24 2.43E‑05 1.22E‑04 3.06E‑03 1.35E‑03
>
> 48 1.18E‑07 5.92E‑07 1.49E‑05 6.57E‑06
>
> 96 2.80E‑12 1.40E‑11 3.52E‑10 1.55E‑10
>
> 120 1.36E‑14 6.80E‑14 1.71E‑12 7.55E‑13
>
> 168 0.00E+00 0.00E+00 0.00E+00 0.00E+00
>
> 336 0.00E+00 0.00E+00 0.00E+00 0.00E+00
>
> 672 0.00E+00 0.00E+00 0.00E+00 0.00E+00
>
> Tc‑99m DTPA, A(0) = 20 mCi, max concentration, half-time:
>
> 3 4.78E‑02 2.39E‑01 6.02E+00 2.65E+00
>
> 12 1.38E‑02 6.88E‑02 1.73E+00 7.64E‑01
>
> 24 2.61E‑03 1.31E‑02 3.29E‑01 1.45E‑01
>
> 48 9.43E‑05 4.72E‑04 1.19E‑02 5.24E‑03
>
> 96 1.23E‑07 6.14E‑07 1.55E‑05 6.82E‑06
>
> 120 4.43E‑09 2.22E‑08 5.58E‑07 2.46E‑07
>
> 168 5.77E‑12 2.89E‑11 7.26E‑10 3.20E‑10
>
> 336 0.00E+00 0.00E+00 0.00E+00 0.00E+00
>
> 672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Table 4 (cont\'d)

Cumulative Activity Ingested and Radiation Doses Received

from the Radiopharmaceuticals Considered in this Report

Under Different Interruption Schedules

Cumulative Activity Effective Dose

Interruption [Ingested]{.underline} [Equivalent (mrem)]{.underline}

[Time (hr)]{.underline} [mCi]{.underline} [percent]{.underline}
[Newborn]{.underline} [1-Yr-Old]{.underline}

Tc‑99m MAA, A(0) = 4 mCi, min concentration, half-time:

3 6.66E‑03 1.66E‑01 4.19E+00 1.70E+00

12 7.11E‑04 1.78E‑02 4.47E‑01 1.81E‑01

24 3.60E‑05 9.00E‑04 2.26E‑02 9.19E‑03

48 9.23E‑08 2.31E‑06 5.81E‑05 2.36E‑05

96 6.07E‑13 1.52E‑11 3.82E‑10 1.55E‑10

120 1.54E‑15 3.85E‑14 9.69E‑13 3.93E‑13

168 0.00E+00 0.00E+00 0.00E+00 0.00E+00

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m MAA, A(0) = 4 mCi, max concentration, half-time:

3 4.78E‑01 1.19E+01 3.01E+02 1.22E+02

12 1.47E‑01 3.68E+01 9.27E+01 3.76E+01

24 3.07E‑02 7.68E‑01 1.93E+01 7.84E+00

48 1.33E‑03 3.33E‑02 8.38E‑01 3.40E‑01

96 2.51E‑06 6.28E‑05 1.58E‑03 6.41E‑04

120 1.09E‑07 2.73E‑06 6.86E‑05 2.78E‑05

168 2.06E‑10 5.14E‑09 1.29E‑07 5.25E‑08

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m O4, A(0) = 30 mCi, min concentration, half-time:

3 4.78E‑02 1.59E‑01 1.95E+01 9.02E+00

12 5.10E‑03 1.70E‑02 2.08E+00 9.63E‑01

24 2.58E‑04 8.61E‑04 1.05E‑01 4.88E‑02

48 6.63E‑07 2.21E‑06 2.70E‑04 1.25E‑04

96 4.36E‑12 1.45E‑11 1.77E‑09 8.23E‑10

120 1.11E‑14 3.69E‑14 4.50E‑12 2.09E‑12

168 0.00E+00 0.00E+00 0.00E+00 0.00E+00

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m O4, A(0) = 30 mCi, max concentration, half-time:

3 2.03E+00 6.76E+00 8.25E+02 3.83E+02

12 6.54E‑01 2.18E+00 2.66E+02 1.23E+02

24 1.44E‑01 4.81E‑01 5.88E+01 2.73E+01

48 7.05E‑03 2.35E‑02 2.87E+00 1.33E+00

96 1.68E‑05 5.61E‑05 6.84E‑03 3.17E‑03

120 8.21E‑07 2.74E‑06 3.34E‑04 1.55E‑04

168 1.96E‑09 6.53E‑09 7.97E‑07 3.69E‑07

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Table 4 (cont\'d)

Cumulative Activity Ingested and Radiation Doses Received

from the Radiopharmaceuticals Considered in this Report

Under Different Interruption Schedules

Cumulative Activity Effective Dose

Interruption [Ingested]{.underline} [Equivalent (mrem)]{.underline}

[Time (hr)]{.underline} [mCi]{.underline} [percent]{.underline}
[Newborn]{.underline} [1-Yr-Old]{.underline}

I‑131 NaI, A(0) = 150 mCi, min concentration, half-time:

3 1.06E+00 7.07E‑01 2.08E+07\* 1.53E+07\*

12 4.52E‑01 3.01E‑01 8.86E+06\* 6.52E+06\*

24 1.45E‑01 9.66E‑02 2.84E+06\* 2.09E+06\*

48 1.49E‑02 9.94E‑03 2.92E+05\* 2.15E+05\*

96 1.58E‑04 1.05E‑04 3.10E+03\* 2.28E+03\*

120 1.62E‑05 1.08E‑05 3.18E+02\* 2.33E+02\*

168 1.71E‑07 1.14E‑07 3.35E+00\* 2.47E+00\*

336 1.92E‑14 1.28E‑14 3.76E‑07\* 2.77E‑07\*

672 0.00E+00 0.00E+00 0.00E+00\* 0.00E+00\*

I‑131 NaI, A(0) = 150 mCi, max concentration, half-time:

3 7.50E+01 5.00E+01 1.47E+09\* 1.08E+09\*

12 7.50E+01 5.00E+01 1.47E+09\* 1.08E+09\*

24 7.50E+01 5.00E+01 1.47E+09\* 1.08E+09\*

48 7.50E+01 5.00E+01 1.47E+09\* 1.08E+09\*

96 7.50E+01 5.00E+01 1.47E+09\* 1.08E+09\*

120 7.50E+01 5.00E+01 1.47E+09\* 1.08E+09\*

168 7.50E+01 5.00E+01 1.47E+09\* 1.08E+09\*

336 1.88E+01 1.25E+01 3.69E+08\* 2.71E+08\*

672 7.68E‑01 5.12E‑01 1.51E+07\* 1.11E+07\*

Cr‑51 EDTA, A(0) = .05 mCi, min concentration, half-time:

3 7.71E‑06 1.54E‑02 8.85E‑04 3.71E‑04

12 3.14E‑06 6.27E‑03 3.60E‑04 1.51E‑04

24 9.44E‑07 1.89E‑03 1.08E‑04 4.54E‑05

48 8.55E‑08 1.71E‑04 9.81E‑06 4.11E‑06

96 7.02E‑10 1.40E‑06 8.06E‑08 3.38E‑08

120 6.37E‑11 1.27E‑07 7.30E‑09 3.06E‑09

168 5.23E‑13 1.05E‑09 6.00E‑11 2.51E‑11

336 1.56E‑20 3.12E‑17 1.79E‑18 7.50E‑19

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Cr‑51 EDTA, A(0) = .05 mCi, max concentration, half-time:

3 3.37E‑05 6.75E‑02 3.87E‑03 1.62E‑03

12 1.37E‑05 2.74E‑02 1.57E‑03 6.60E‑04

24 4.13E‑06 8.26E‑03 4.74E‑04 1.99E‑04

48 3.74E‑07 7.48E‑04 4.29E‑05 1.80E‑05

96 3.07E‑09 6.15E‑06 3.53E‑07 1.48E‑07

120 2.79E‑10 5.57E‑07 3.19E‑08 1.34E‑08

168 2.29E‑12 4.58E‑09 2.62E‑10 1.10E‑10

336 6.82E‑20 1.36E‑16 7.82E‑18 3.28E‑18

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

\* Dose to the infant thyroid, mrad.

Table 4 (cont\'d)

Cumulative Activity Ingested and Radiation Doses Received

from the Radiopharmaceuticals Considered in this Report

Under Different Interruption Schedules

Cumulative Activity Effective Dose

Interruption [Ingested]{.underline} [Equivalent (mrem)]{.underline}

[Time (hr)]{.underline} [mCi]{.underline} [percent]{.underline}
[Newborn]{.underline} [1-Yr-Old]{.underline}

Tc‑99m DISIDA, A(0) = 8 mCi, min concentration, half-time:

3 5.64E‑03 7.05E‑02 4.80E+00 2.30E+00

12 1.07E‑03 1.34E‑02 9.12E‑01 4.36E‑01

24 1.17E‑04 1.46E‑03 9.95E‑02 4.76E‑02

48 1.39E‑06 1.74E‑05 1.18E‑03 5.67E‑04

96 1.97E‑10 2.47E‑09 1.68E‑07 8.03E‑08

120 2.35E‑12 2.94E‑11 2.00E‑09 9.57E‑10

168 3.21E‑16 4.02E‑15 2.73E‑13 1.31E‑13

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m DISIDA, A(0) = 8 mCi, max concentration, half-time:

3 2.25E‑02 2.82E‑01 1.92E+01 9.17E+00

12 1.13E‑02 1.42E‑01 9.66E+00 4.62E+00

24 4.55E‑03 5.69E‑02 3.87E+00 1.85E+00

48 7.32E‑04 9.15E‑03 6.23E‑01 2.98E‑01

96 1.89E‑05 2.36E‑04 1.61E‑02 7.70E‑03

120 3.04E‑06 3.80E‑05 2.59E‑03 1.24E‑03

168 7.86E‑08 9.83E‑07 6.69E‑05 3.20E‑05

336 2.18E‑13 2.73E‑12 1.86E‑10 8.89E‑11

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m gluco, A(0) = 20 mCi, min concentration, half-time:

3 1.48E‑02 7.41E‑02 2.30E+00 5.38E+00

12 2.63E‑03 1.31E‑02 4.08E‑01 9.52E‑01

24 2.61E‑04 1.31E‑03 4.06E‑02 9.48E‑02

48 2.59E‑06 1.29E‑05 4.02E‑04 9.38E‑04

96 2.53E‑10 1.27E‑09 3.94E‑08 9.19E‑08

120 2.51E‑12 1.25E‑11 3.90E‑10 9.10E‑10

168 2.21E‑16 1.11E‑15 3.44E‑14 8.03E‑14

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m gluco, A(0) = 20 mCi, max concentration, half-time:

3 3.02E‑02 1.51E‑01 4.70E+00 1.10E+01

12 6.37E‑03 3.19E‑02 9.90E‑01 2.31E+00

24 7.99E‑04 3.99E‑03 1.24E‑01 2.90E‑01

48 1.25E‑05 6.27E‑05 1.95E‑03 4.55E‑03

96 3.10E‑09 1.55E‑08 4.81E‑07 1.12E‑06

120 4.87E‑11 2.43E‑10 7.56E‑09 1.76E‑08

168 1.19E‑14 5.97E‑14 1.86E‑12 4.33E‑12

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Table 4 (cont\'d)

Cumulative Activity Ingested and Radiation Doses Received

from the Radiopharmaceuticals Considered in this Report

Under Different Interruption Schedules

Cumulative Activity Effective Dose

Interruption [Ingested]{.underline} [Equivalent (mrem)]{.underline}

[Time (hr)]{.underline} [mCi]{.underline} [percent]{.underline}
[Newborn]{.underline} [1-Yr-Old]{.underline}

Tc‑99m HAM, A(0) = 8 mCi, min concentration, half-time:

3 3.60E‑02 4.50E‑01 2.00E+01 8.13E+00

12 4.51E‑03 5.64E‑02 2.50E+00 1.02E+00

24 2.83E‑04 3.54E‑03 1.57E‑01 6.38E‑02

48 1.11E‑06 1.39E‑05 6.17E‑04 2.51E‑04

96 1.72E‑11 2.14E‑10 9.52E‑09 3.87E‑09

120 6.73E‑14 8.42E‑13 3.74E‑11 1.52E‑11

168 0.00E+00 0.00E+00 0.00E+00 0.00E+00

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m HAM, A(0) = 8 mCi, max concentration, half-time:

3 8.95E‑02 1.12E+00 4.97E+01 2.02E+01

12 3.67E‑02 4.59E‑01 2.04E+01 8.29E+00

24 1.12E‑02 1.40E‑01 6.21E+00 2.53E+00

48 1.04E‑03 1.30E‑02 5.77E‑01 2.35E‑01

96 8.98E‑06 1.12E‑04 4.98E‑03 2.03E‑03

120 8.35E‑07 1.04E‑05 4.63E‑04 1.88E‑04

168 7.21E‑09 9.01E‑08 4.00E‑06 1.63E‑06

336 3.00E‑16 3.75E‑15 1.66E‑13 6.76E‑14

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m MIBI, A(0) = 30 mCi, min concentration, half-time:

3 2.23E‑03 7.44E‑03 1.16E+00 5.37E‑01

12 5.59E‑04 1.86E‑03 2.90E‑01 1.34E‑01

24 8.83E‑05 2.94E‑04 4.57E‑02 2.12E‑02

48 2.20E‑06 7.34E‑06 1.14E‑03 5.30E‑04

96 1.37E‑09 4.56E‑09 7.09E‑07 3.29E‑07

120 3.41E‑11 1.14E‑10 1.77E‑08 8.21E‑09

168 2.12E‑14 7.08E‑14 1.10E‑11 5.11E‑12

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m MIBI, A(0) = 30 mCi, max concentration, half-time:

3 1.97E‑02 6.56E‑02 1.02E+01 4.73E+00

12 7.76E‑03 2.59E‑02 4.02E+00 1.87E+00

24 2.24E‑03 7.47E‑03 1.16E+00 5.39E‑01

48 1.87E‑04 6.24E‑04 9.70E‑02 4.51E‑02

96 1.31E‑06 4.36E‑06 6.77E‑04 3.14E‑04

120 1.09E‑07 3.64E‑07 5.66E‑05 2.63E‑05

168 7.62E‑10 2.54E‑09 3.95E‑07 1.83E‑07

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Table 4 (cont\'d)

Cumulative Activity Ingested and Radiation Doses Received

from the Radiopharmaceuticals Considered in this Report

Under Different Interruption Schedules

Cumulative Activity Effective Dose

Interruption [Ingested]{.underline} [Equivalent (mrem)]{.underline}

[Time (hr)]{.underline} [mCi]{.underline} [percent]{.underline}
[Newborn]{.underline} [1-Yr-Old]{.underline}

Tc‑99m MDP, A(0) = 20 mCi, min concentration, half-time:

3 8.94E‑03 4.47E‑02 3.64E+00 1.39E+00

12 1.51E‑03 7.53E‑03 6.13E‑01 2.34E‑01

24 1.40E‑04 7.02E‑04 5.71E‑02 2.18E‑02

48 1.22E‑06 6.09E‑06 4.95E‑04 1.89E‑04

96 9.16E‑11 4.58E‑10 3.73E‑08 1.42E‑08

120 7.94E‑13 3.97E‑12 3.23E‑10 1.23E‑10

168 4.15E‑17 2.08E‑16 1.69E‑14 6.45E‑15

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m MDP, A(0) = 20 mCi, max concentration, half-time:

3 1.20E‑02 5.98E‑02 4.87E+00 1.86E+00

12 3.53E‑03 1.76E‑02 1.44E+00 5.48E‑01

24 6.92E‑04 3.46E‑03 2.82E‑01 1.08E‑01

48 2.67E‑05 1.33E‑04 1.09E‑02 4.14E‑03

96 3.96E‑08 1.98E‑07 1.61E‑05 6.15E‑06

120 1.52E‑09 7.62E‑09 6.20E‑07 2.37E‑07

168 2.26E‑12 1.13E‑11 9.20E‑10 3.51E‑10

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m PYP, A(0) = 20 mCi, min concentration, half-time:

3 1.73E‑02 8.66E‑02 4.81E+00 2.05E+00

12 2.92E‑03 1.46E‑02 8.10E‑01 3.46E‑01

24 2.72E‑04 1.36E‑03 7.55E‑02 3.22E‑02

48 2.36E‑06 1.18E‑05 6.54E‑04 2.79E‑04

96 1.77E‑10 8.87E‑10 4.92E‑08 2.10E‑08

120 1.54E‑12 7.70E‑12 4.27E‑10 1.82E‑10

168 8.05E‑17 4.02E‑16 2.23E‑14 9.53E‑15

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m PYP, A(0) = 20 mCi, max concentration, half-time:

3 8.73E‑02 4.37E‑01 2.42E+01 1.03E+01

12 3.49E‑02 1.74E‑01 9.68E+00 4.13E+00

24 1.03E‑02 5.14E‑02 2.85E+00 1.22E+00

48 8.90E‑04 4.45E‑03 2.47E‑01 1.05E‑01

96 6.68E‑06 3.34E‑05 1.85E‑03 7.91E‑04

120 5.79E‑07 2.90E‑06 1.61E‑04 6.86E‑05

168 4.35E‑09 2.17E‑08 1.21E‑06 5.15E‑07

336 4.20E‑17 2.10E‑16 1.17E‑14 4.97E‑15

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Table 4 (cont\'d)

Cumulative Activity Ingested and Radiation Doses Received

from the Radiopharmaceuticals Considered in this Report

Under Different Interruption Schedules

Cumulative Activity Effective Dose

Interruption [Ingested]{.underline} [Equivalent (mrem)]{.underline}

[Time (hr)]{.underline} [mCi]{.underline} [percent]{.underline}
[Newborn]{.underline} [1-Yr-Old]{.underline}

Tc‑99m RBC vivo, A(0) = 20 mCi, min concentration, half-time:

3 9.49E‑04 4.75E‑03 2.88E‑01 1.30E‑01

12 3.79E‑04 1.90E‑03 1.15E‑01 5.19E‑02

24 1.12E‑04 5.58E‑04 3.39E‑02 1.53E‑02

48 9.67E‑06 4.84E‑05 2.94E‑03 1.32E‑03

96 7.26E‑08 3.63E‑07 2.20E‑05 9.94E‑06

120 6.29E‑09 3.15E‑08 1.91E‑06 8.62E‑07

168 4.73E‑11 2.36E‑10 1.43E‑08 6.47E‑09

336 4.57E‑19 2.28E‑18 1.39E‑16 6.25E‑17

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m RBC vivo, A(0) = 20 mCi, max concentration, half-time:

3 4.38E‑01 2.19E+00 1.33E+02 5.99E+01

12 1.80E‑01 8.98E‑01 5.45E+01 2.46E+01

24 5.48E‑02 2.74E‑01 1.66E+01 7.50E+00

48 5.09E‑03 2.54E‑02 1.54E+00 6.96E‑01

96 4.39E‑05 2.20E‑04 1.33E‑02 6.01E‑03

120 4.08E‑06 2.04E‑05 1.24E‑03 5.59E‑04

168 3.52E‑08 1.76E‑07 1.07E‑05 4.82E‑06

336 1.47E‑15 7.33E‑15 4.45E‑13 2.01E‑13

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m RBC vitro, A(0) = 20 mCi, min concentration, half-time:

3 3.53E‑03 1.76E‑02 1.10E+00 4.83E‑01

12 1.58E‑03 7.92E‑03 4.93E‑01 2.17E‑01

24 5.46E‑04 2.73E‑03 1.70E‑01 7.47E‑02

48 6.47E‑05 3.24E‑04 2.01E‑02 8.86E‑03

96 9.10E‑07 4.55E‑06 2.83E‑04 1.25E‑04

120 1.08E‑07 5.39E‑07 3.35E‑05 1.48E‑05

168 1.52E‑09 7.58E‑09 4.71E‑07 2.08E‑07

336 4.95E‑16 2.48E‑15 1.54E‑13 6.78E‑14

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m RBC vitro, A(0) = 20 mCi, max concentration, half-time:

3 6.06E‑03 3.03E‑02 1.88E+00 8.30E‑01

12 3.03E‑03 1.52E‑02 9.42E‑01 4.15E‑01

24 1.20E‑03 6.01E‑03 3.74E‑01 1.65E‑01

48 1.90E‑04 9.48E‑04 5.89E‑02 2.59E‑02

96 4.70E‑06 2.35E‑05 1.46E‑03 6.44E‑04

120 7.41E‑07 3.71E‑06 2.30E‑04 1.01E‑04

168 1.84E‑08 9.20E‑08 5.72E‑06 2.52E‑06

336 4.43E‑14 2.22E‑13 1.38E‑11 6.07E‑12

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Table 4 (cont\'d)

Cumulative Activity Ingested and Radiation Doses Received

from the Radiopharmaceuticals Considered in this Report

Under Different Interruption Schedules

Cumulative Activity Effective Dose

Interruption [Ingested]{.underline} [Equivalent (mrem)]{.underline}

[Time (hr)]{.underline} [mCi]{.underline} [percent]{.underline}
[Newborn]{.underline} [1-Yr-Old]{.underline}

Tc‑99m SC, A(0) = 12 mCi, min concentration, half-time:

3 1.26E‑02 1.05E‑01 9.33E+00 4.57E+00

12 3.74E‑03 3.11E‑02 2.76E+00 1.35E+00

24 7.38E‑04 6.15E‑03 5.46E‑01 2.68E‑01

48 2.88E‑05 2.40E‑04 2.13E‑02 1.05E‑02

96 4.40E‑08 3.67E‑07 3.26E‑05 1.60E‑05

120 1.72E‑09 1.43E‑08 1.27E‑06 6.23E‑07

168 2.62E‑12 2.19E‑11 1.94E‑09 9.51E‑10

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m SC, A(0) = 12 mCi, max concentration, half-time:

3 1.76E‑01 1.47E+00 1.30E+02 6.38E+01

12 8.30E‑02 6.92E‑01 6.14E+01 3.01E+01

24 3.05E‑02 2.54E‑01 2.26E+01 1.11E+01

48 4.11E‑03 3.42E‑02 3.04E+00 1.49E+00

96 7.47E‑05 6.22E‑04 5.53E‑02 2.71E‑02

120 1.01E‑05 8.39E‑05 7.45E‑03 3.65E‑03

168 1.83E‑07 1.53E‑06 1.35E‑04 6.64E‑05

336 1.48E‑13 1.23E‑12 1.09E‑10 5.36E‑11

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

In‑111 WBC, A(0) = .5 mCi, min concentration, half-time:

3 6.21E‑04 1.24E‑01 2.04E+01 8.04E+00

12 5.77E‑04 1.15E‑01 1.90E+01 7.47E+00

24 5.23E‑04 1.05E‑01 1.72E+01 6.77E+00

48 4.30E‑04 8.60E‑02 1.42E+01 5.57E+00

96 2.91E‑04 5.82E‑02 9.58E+00 3.77E+00

120 2.39E‑04 4.78E‑02 7.88E+00 3.10E+00

168 1.62E‑04 3.23E‑02 5.32E+00 2.09E+00

336 4.11E‑05 8.22E‑03 1.35E+00 5.32E‑01

672 2.66E‑06 5.31E‑04 8.75E‑02 3.44E‑02

In‑111 WBC, A(0) = .5 mCi, max concentration, half-time:

3 3.10E‑03 6.19E‑01 1.02E+02 4.01E+01

12 2.96E‑03 5.92E‑01 9.75E+01 3.83E+01

24 2.79E‑03 5.58E‑01 9.19E+01 3.61E+01

48 2.48E‑03 4.95E‑01 8.16E+01 3.21E+01

96 1.95E‑03 3.91E‑01 6.43E+01 2.53E+01

120 1.73E‑03 3.47E‑01 5.71E+01 2.25E+01

168 1.37E‑03 2.74E‑01 4.50E+01 1.77E+01

336 5.95E‑04 1.19E‑01 1.96E+01 7.71E+00

672 1.13E‑04 2.26E‑02 3.72E+00 1.46E+00

Table 4 (cont\'d)

Cumulative Activity Ingested and Radiation Doses Received

from the Radiopharmaceuticals Considered in this Report

Under Different Interruption Schedules

Cumulative Activity Effective Dose

Interruption [Ingested]{.underline} [Equivalent (mrem)]{.underline}

[Time (hr)]{.underline} [mCi]{.underline} [percent]{.underline}
[Newborn]{.underline} [1-Yr-Old]{.underline}

I‑123 NaI, A(0) = .4 mCi, min concentration, half-time:

3 1.03E‑02 2.58E+00 6.11E+01 4.20E+01

12 3.53E‑03 8.83E‑01 2.09E+01 1.44E+01

24 8.45E‑04 2.11E‑01 5.00E+00 3.44E+00

48 4.84E‑05 1.21E‑02 2.87E‑01 1.97E‑01

96 1.59E‑07 3.98E‑05 9.42E‑04 6.48E‑04

120 9.12E‑09 2.28E‑06 5.40E‑05 3.71E‑05

168 3.00E‑11 7.49E‑09 1.77E‑07 1.22E‑07

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

I‑123 NaI, A(0) = .4 mCi, max concentration, half-time:

3 1.08E‑02 2.70E+00 6.40E+01 4.40E+01

12 3.70E‑03 9.25E‑01 2.19E+01 1.51E+01

24 8.86E‑04 2.22E‑01 5.25E+00 3.61E+00

48 5.08E‑05 1.27E‑02 3.01E‑01 2.07E‑01

96 1.67E‑07 4.17E‑05 9.88E‑04 6.79E‑04

120 9.56E‑09 2.39E‑06 5.66E‑05 3.89E‑05

168 3.14E‑11 7.85E‑09 1.86E‑07 1.28E‑07

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

I‑123 OIH, A(0) = 2 mCi, min concentration, half-time:

3 1.63E‑02 8.13E‑01 3.85E+00 1.62E+00

12 2.76E‑03 1.38E‑01 6.54E‑01 2.76E‑01

24 2.60E‑04 1.30E‑02 6.16E‑02 2.60E‑02

48 2.31E‑06 1.15E‑04 5.47E‑04 2.31E‑04

96 1.82E‑10 9.08E‑09 4.30E‑08 1.82E‑08

120 1.61E‑12 8.06E‑11 3.82E‑10 1.61E‑10

168 8.79E‑17 4.40E‑15 2.08E‑14 8.78E‑15

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

I‑123 OIH, A(0) = 2 mCi, max concentration, half-time:

3 1.24E‑01 6.18E+00 2.93E+01 1.24E+01

12 4.18E‑02 2.09E+00 9.91E+00 4.18E+00

24 9.86E‑03 4.93E‑01 2.33E+00 9.85E‑01

48 5.48E‑04 2.74E‑02 1.30E‑01 5.47E‑02

96 1.69E‑06 8.45E‑05 4.00E‑04 1.69E‑04

120 9.38E‑08 4.69E‑06 2.22E‑05 9.37E‑06

168 2.89E‑10 1.45E‑08 6.85E‑08 2.89E‑08

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Table 4 (cont\'d)

Cumulative Activity Ingested and Radiation Doses Received

from the Radiopharmaceuticals Considered in this Report

Under Different Interruption Schedules

Cumulative Activity Effective Dose

Interruption [Ingested]{.underline} [Equivalent (mrem)]{.underline}

[Time (hr)]{.underline} [mCi]{.underline} [percent]{.underline}
[Newborn]{.underline} [1-Yr-Old]{.underline}

I‑123 mIBG, A(0) = 10 mCi, min concentration, half-time:

3 5.41E‑02 5.41E‑01 3.20E+02 2.20E+02

12 3.13E‑02 3.13E‑01 1.86E+02 1.28E+02

24 1.51E‑02 1.51E‑01 8.96E+01 6.16E+01

48 3.53E‑03 3.53E‑02 2.09E+01 1.44E+01

96 1.92E‑04 1.92E‑03 1.14E+00 7.82E‑01

120 4.48E‑05 4.48E‑04 2.65E‑01 1.82E‑01

168 2.44E‑06 2.44E‑05 1.44E‑02 9.92E‑03

336 9.15E‑11 9.15E‑10 5.42E‑07 3.73E‑07

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

I‑123 mIBG, A(0) = 10 mCi, max concentration, half-time:

3 5.41E‑02 5.41E‑01 3.20E+02 2.20E+02

12 3.13E‑02 3.13E‑01 1.86E+02 1.28E+02

24 1.51E‑02 1.51E‑01 8.96E+01 6.16E+01

48 3.53E‑03 3.53E‑02 2.09E+01 1.44E+01

96 1.92E‑04 1.92E‑03 1.14E+00 7.82E‑01

120 4.48E‑05 4.48E‑04 2.65E‑01 1.82E‑01

168 2.44E‑06 2.44E‑05 1.44E‑02 9.92E‑03

336 9.15E‑11 9.15E‑10 5.42E‑07 3.73E‑07

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

I‑125 OIH, A(0) = .01 mCi, min concentration, half-time:

3 2.52E‑04 2.52E+00 2.24E‑01 9.04E‑02

12 6.84E‑05 6.84E‑01 6.07E‑02 2.45E‑02

24 1.20E‑05 1.20E‑01 1.07E‑02 4.31E‑03

48 3.72E‑07 3.72E‑03 3.30E‑04 1.33E‑04

96 3.55E‑10 3.55E‑06 3.15E‑07 1.27E‑07

120 1.10E‑11 1.10E‑07 9.75E‑09 3.94E‑09

168 1.05E‑14 1.05E‑10 9.32E‑12 3.77E‑12

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

I‑125 OIH, A(0) = .01 mCi, max concentration, half-time:

3 2.52E‑04 2.52E+00 2.24E‑01 9.04E‑02

12 6.84E‑05 6.84E‑01 6.07E‑02 2.54E‑02

24 1.20E‑05 1.20E‑01 1.07E‑02 4.31E‑03

48 3.72E‑07 3.72E‑03 3.30E‑04 1.33E‑04

96 3.55E‑10 3.55E‑06 3.15E‑07 1.27E‑07

120 1.10E‑11 1.10E‑07 9.75E‑09 3.94E‑09

168 1.05E‑14 1.05E‑10 9.32E‑12 3.77E‑12

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Table 4 (cont\'d)

Cumulative Activity Ingested and Radiation Doses Received

from the Radiopharmaceuticals Considered in this Report

Under Different Interruption Schedules

Cumulative Activity Effective Dose

Interruption [Ingested]{.underline} [Equivalent (mrem)]{.underline}

[Time (hr)]{.underline} [mCi]{.underline} [percent]{.underline}
[Newborn]{.underline} [1-Yr-Old]{.underline}

I‑131 OIH, A(0) = .3 mCi, min concentration, half-time:

3 2.62E‑03 8.73E‑01 2.91E+00 1.16E+00

12 1.49E‑04 4.96E‑02 1.65E‑01 6.61E‑02

24 3.26E‑06 1.09E‑03 3.61E‑03 1.45E‑03

48 1.56E‑09 5.19E‑07 1.73E‑06 6.91E‑07

96 3.48E‑16 1.16E‑13 3.86E‑13 1.54E‑13

120 0.00E+00 0.00E+00 0.00E+00 0.00E+00

168 0.00E+00 0.00E+00 0.00E+00 0.00E+00

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

I‑131 OIH, A(0) = .3 mCi, max concentration, half-time:

3 1.50E‑02 4.99E+00 1.66E+01 6.65E+00

12 5.13E‑03 1.71E+00 5.69E+00 2.28E+00

24 1.23E‑03 4.09E‑01 1.36E+00 5.45E‑01

48 7.05E‑05 2.35E‑02 7.82E‑02 3.13E‑02

96 2.32E‑07 7.73E‑05 2.58E‑04 1.03E‑04

120 1.33E‑08 4.44E‑06 1.48E‑05 5.91E‑06

168 4.38E‑11 1.46E‑08 4.86E‑08 1.95E‑08

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tl‑201 Cl, A(0) = 3 mCi, min concentration, t~1/2~:

3 1.22E‑02 4.08E‑01 1.84E+02 1.04E+02

12 9.72E‑03 3.24E‑01 1.46E+02 8.26E+01

24 7.49E‑03 2.50E‑01 1.12E+02 6.36E+01

48 4.92E‑03 1.64E‑01 7.38E+01 4.18E+01

96 2.45E‑03 8.17E‑02 3.68E+01 2.08E+01

120 1.76E‑03 5.86E‑02 2.64E+01 1.50E+01

168 9.10E‑04 3.03E‑02 1.36E+01 7.74E+00

336 9.11E‑05 3.04E‑03 1.37E+00 7.74E‑01

672 9.13E‑07 3.04E‑05 1.37E‑02 7.76E‑03

Tl‑201 Cl, A(0) = 3 mCi, max concentration, t~1/2~:

3 2.37E‑02 7.91E‑01 3.55E+02 2.01E+02

12 2.12E‑02 7.08E‑01 3.18E+02 1.80E+02

24 1.86E‑02 6.21E‑01 2.79E+02 1.58E+02

48 1.51E‑02 5.04E‑01 2.26E+02 1.28E+02

96 1.16E‑02 3.88E‑01 1.74E+02 9.86E+01

120 1.07E‑02 3.56E‑01 1.60E+02 9.10E+01

168 9.41E‑03 3.14E‑01 1.41E+02 8.00E+01

336 6.71E‑03 2.24E‑01 1.01E+02 5.70E+01

672 3.53E‑03 1.18E‑01 5.30E+01 3.00E+01

Table 4 (cont\'d)

Cumulative Activity Ingested and Radiation Doses Received

from the Radiopharmaceuticals Considered in this Report

Under Different Interruption Schedules

Cumulative Activity Effective Dose

Interruption [Ingested]{.underline} [Equivalent (mrem)]{.underline}

[Time (hr)]{.underline} [mCi]{.underline} [percent]{.underline}
[Newborn]{.underline} [1-Yr-Old]{.underline}

Tc‑99m DTPA Aer, A(0) = 1 mCi, min concentration, half-time:

3 5.14E‑05 5.14E‑03 1.43E‑02 6.09E‑03

12 6.98E‑06 6.98E‑04 1.94E‑03 8.26E‑04

24 4.87E‑07 4.87E‑05 1.35E‑04 5.76E‑05

48 2.37E‑09 2.37E‑07 6.57E‑07 2.80E‑07

96 5.60E‑14 5.60E‑12 1.55E‑11 6.63E‑12

120 2.72E‑16 2.72E‑14 7.55E‑14 3.22E‑14

168 0.00E+00 0.00E+00 0.00E+00 0.00E+00

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m DTPA Aer, A(0) = 1 mCi, max concentration, half-time:

3 9.93E‑04 9.93E‑02 2.76E‑01 1.18E‑01

12 2.86E‑04 2.86E‑02 7.93E‑02 3.38E‑02

24 5.43E‑05 5.43E‑03 1.51E‑02 6.43E‑03

48 1.96E‑06 1.96E‑04 5.44E‑04 2.32E‑04

96 2.55E‑09 2.55E‑07 7.08E‑07 3.02E‑07

120 9.21E‑11 9.21E‑09 2.56E‑08 1.09E‑08

168 1.20E‑13 1.20E‑11 3.33E‑11 1.42E‑11

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m MAG3, A(0) = 10 mCi, min concentration, half-time:

3 1.29E‑03 1.29E‑02 1.52E‑01 6.66E‑02

12 1.74E‑04 1.74E‑03 2.07E‑02 9.04E‑03

24 1.22E‑05 1.22E‑04 1.44E‑03 6.30E‑04

48 5.92E‑08 5.92E‑07 7.00E‑06 3.06E‑06

96 1.40E‑12 1.40E‑11 1.66E‑10 7.25E‑11

120 6.80E‑15 6.80E‑14 8.05E‑13 3.52E‑13

168 0.00E+00 0.00E+00 0.00E+00 0.00E+00

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m MAG3, A(0) = 10 mCi, max concentration, half-time:

3 2.39E‑02 2.39E‑01 2.83E+00 1.24E+00

12 6.88E‑03 6.88E‑02 8.15E‑01 3.56E‑01

24 1.31E‑03 1.31E‑02 1.55E‑01 6.77E‑02

48 4.72E‑05 4.72E‑04 5.58E‑03 2.44E‑03

96 6.14E‑08 6.14E‑07 7.27E‑06 3.18E‑06

120 2.22E‑09 2.22E‑08 2.62E‑07 1.15E‑07

168 2.89E‑12 2.89E‑11 3.42E‑10 1.50E‑10

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Table 4 (cont\'d)

Cumulative Activity Ingested and Radiation Doses Received

from the Radiopharmaceuticals Considered in this Report

Under Different Interruption Schedules

Cumulative Activity Effective Dose

Interruption [Ingested]{.underline} [Equivalent (mrem)]{.underline}

[Time (hr)]{.underline} [mCi]{.underline} [percent]{.underline}
[Newborn]{.underline} [1-Yr-Old]{.underline}

Tc‑99m WBC, A(0) = 30 mCi, min concentration, half-time:

3 4.78E‑02 1.59E‑01 1.95E+01 9.02E+00

12 5.10E‑03 1.70E‑02 2.08E+00 9.63E‑01

24 2.58E‑04 8.61E‑04 1.05E‑01 4.88E‑02

48 6.63E‑07 2.21E‑06 2.70E‑04 1.25E‑04

96 4.36E‑12 1.45E‑11 1.77E‑09 8.23E‑10

120 1.11E‑14 3.69E‑14 4.50E‑12 2.09E‑12

168 0.00E+00 0.00E+00 0.00E+00 0.00E+00

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00

Tc‑99m WBC, A(0) = 30 mCi, max concentration, half-time:

3 2.03E+00 6.76E+00 8.25E+02 3.83E+02

12 6.54E‑01 2.18E+00 2.66E+02 1.23E+02

24 1.44E‑01 4.81E‑01 5.88E+01 2.73E+01

48 7.05E‑03 2.35E‑02 2.87E+00 1.33E+00

96 1.68E‑05 5.61E‑05 6.84E‑03 3.17E‑03

120 8.21E‑07 2.74E‑06 3.34E‑04 1.55E‑04

168 1.96E‑09 6.53E‑09 7.97E‑07 3.69E‑07

336 0.00E+00 0.00E+00 0.00E+00 0.00E+00

672 0.00E+00 0.00E+00 0.00E+00 0.00E+00